SNGX · Soligenix, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $2.3K | $117.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | $2.3K | $117.0K | - |
| Gross Profit | - | - | - | - | - | - | - | $0 | $0 | - |
| R&D | $1.78M | - | $1.58M | $1.68M | $2.23M | - | $968.7K | $501.2K | $1.10M | - |
| SG&A | $1.10M | - | $996.6K | $1.09M | $1.08M | - | $896.5K | $1.24M | $1.02M | - |
| Total Operating Expenses | $2.88M | - | $2.58M | $2.76M | $3.31M | - | $1.87M | $1.74M | $2.12M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($2.88M) | - | ($2.58M) | ($2.76M) | ($3.31M) | - | ($1.87M) | ($1.74M) | ($2.12M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.82M) | - | ($2.53M) | ($2.70M) | ($3.24M) | - | ($1.72M) | ($1.64M) | ($1.92M) | - |
| EPS - Basic | ($0.28) | - | ($0.58) | ($0.82) | ($1.06) | - | ($0.78) | ($1.31) | ($2.88) | - |
| EPS - Diluted | ($0.28) | - | ($0.58) | ($0.82) | ($1.06) | - | ($0.78) | ($1.31) | ($2.88) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.03M | $7.94M | $10.53M | $5.10M | $7.30M | $7.82M | $9.84M | $9.41M | $7.09M | $8.45M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $828.7K | $1.12M | $1.21M | $650.0K | $599.7K | $667.9K | $891.2K | $1.70M | $1.44M | $1.11M |
| Current Assets | $6.57M | $8.85M | $10.88M | $5.32M | $7.64M | $8.83M | $10.31M | $9.66M | $7.82M | $9.51M |
| Total Assets | $6.92M | $9.24M | $11.29M | $5.76M | $7.75M | $8.97M | $10.48M | $9.87M | $8.06M | $9.80M |
| Current Liabilities | $3.62M | $3.70M | $3.42M | $3.63M | - | $4.85M | $4.53M | $6.35M | $7.21M | $6.15M |
| Long-term Debt | - | - | - | - | - | $0 | - | - | - | $1.01M |
| Total Liabilities | $3.83M | $3.94M | $3.70M | $3.93M | $4.13M | $4.85M | $4.54M | $6.40M | $7.29M | $7.27M |
| Stockholders' Equity | $3.09M | $5.29M | $7.60M | $1.83M | $3.61M | $4.12M | $5.94M | $3.46M | $768.4K | $2.52M |
| Retained Earnings | ($247.88M) | ($245.05M) | ($242.15M) | ($239.62M) | ($237.21M) | ($233.97M) | ($230.98M) | ($229.26M) | ($227.62M) | ($225.70M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.36M) | - | - | - | ($1.85M) | - | - | - | ($1.34M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $451.0K | - | - | - | $1.32M | - | - | - | ($9.0K) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | 0.0% | 0.0% | - |
| Operating margin | - | - | - | - | - | - | - | -74495.1% | -1809.0% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | -70217.8% | -1636.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | 21398.7% | 935.7% | - |
| SG&A / Revenue | - | - | - | - | - | - | - | 53096.4% | 873.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -40.8% | - | -22.4% | -46.9% | -41.8% | - | -16.4% | -16.7% | -23.8% | - |
| Return on equity | -91.4% | - | -33.3% | -147.7% | -89.6% | - | -29.0% | -47.5% | -249.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.81 | 2.39 | 3.18 | 1.47 | - | 1.82 | 2.28 | 1.52 | 1.08 | 1.55 |
| Quick ratio | 1.81 | 2.39 | 3.18 | 1.47 | - | 1.82 | 2.28 | 1.52 | 1.08 | 1.55 |
| Cash ratio | 1.67 | 2.15 | 3.08 | 1.40 | - | 1.61 | 2.17 | 1.48 | 0.98 | 1.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | - | - | - | 0.40 |
| Debt / Assets | - | - | - | - | - | 0.00 | - | - | - | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.24 | 1.75 | 1.49 | 3.15 | 2.14 | 2.18 | 1.77 | 2.85 | 10.49 | 3.88 |
| Liabilities / Assets | 0.55 | 0.43 | 0.33 | 0.68 | 0.53 | 0.54 | 0.43 | 0.65 | 0.90 | 0.74 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | 0.00 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | 264668d | 4481d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.9x | - | 0.7x | 2.3x | 1.8x | - | 1.5x | 0.9x | 131.5x | - |
| P / S | - | - | - | - | - | - | - | 1386.9x | 863.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | -98.9% | -54.5% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | -77.8% | -7.4% | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | -72.7% | -36.6% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 12.9% | - | -38.3% | -58.4% | -56.4% | - | -4.8% | -7.0% | 1.6% | - |
| Net income growth (YoY) | 12.7% | - | -47.2% | -64.3% | -69.0% | - | -3.4% | -2.0% | -83.1% | - |
| EPS growth (YoY) | 73.6% | - | 25.6% | 37.4% | 63.2% | - | -387.5% | -403.8% | -700.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -14.5% | 28.5% | 28.0% | -47.2% | 370.1% | 63.3% | 40.6% | -40.3% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Business segments
$119.4K totalBio Therapeutics$119.4K · 100.0%
Product / service
$119.4K totalGrant$119.4K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SOLIGENIX against the 5 most active filers in the same SIC group.